Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure
This article was originally published in Scrip
'No surprise' apparently, as GW Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization, Inc. report negative top-line results from the remaining two Phase III trials of their cannabis extract product Sativex (nabiximols) for the treatment of pain in advanced cancer patients who experience inadequate analgesia during optimized chronic opioid therapy.
You may also be interested in...
Vertex hopes to develop CTX001 as a treatment for sickle cell disease and beta thalassemia. Allergan adds stalled uterine fibroid candidate in buyout of troubled Repros, Juno licenses multiple myeloma candidate from Lilly.
The UK group has raised nearly $320m this week which will be used to build commercial organizations in the US and Europe ahead of potential approvals for its cannabinoid epilepsy therapy Epidiolex.
Over 50 cannabinoid drugs are in development, most commonly targeting central nervous system diseases. Analysts think the relaxation of restrictions on medical cannabis is helping with perception problems, but so far there’s little evidence the market isn’t just smoke and mirrors.